Immunotherapy Using CAR T Cells: Current Challenges and Solutions to Overcome On-Target, Off-Tumor Toxicity
DOI:
https://doi.org/10.47611/jsrhs.v12i4.6226Keywords:
Immunotherapy, CAR T cells, On-Target Off-Tumor Toxicity, Epitope Editing, Logic Gating, Antigen EscapeAbstract
Blood cancers like leukemia and lymphoma currently affect approximately 1.3 million Americans and account for about 10% of all cancer related deaths in the US. However, immunotherapies such as chimeric antigen receptor (CAR) T cells have been developed to provide a cure for many of these patients where refractory/relapsed disease was previously a death sentence. Current approaches for CAR T treatment involve the modification of autologous T cells ex vivo in order to engineer these cells with a CAR which binds to a B cell cancer antigen and results in T cell mediated clearance of the target tumor cell. With exception to CD19 and other B cell antigens, targeting other tumor cell types has been largely unsuccessful for many reasons, including antigen escape and on-target off-tumor toxicity (OTOT), which occurs when the target cancer antigen is co-expressed on healthy tissue cells and becomes targeted by the CAR T cell therapy. The purpose of this review is to understand the challenges in antigen escape and OTOT. We will discuss current strategies to overcome these obstacles which allow CAR T therapy to be more applicable to other tumor cell types. We will highlight novel approaches such as logic gated CARs and epitope editing as potential solutions to overcome antigen escape and OTOT.
Downloads
References or Bibliography
Allart-Vorelli, P., Porro, B., Baguet, F., Michel, A., & Cousson-Gélie, F. (2015). Hematological cancer and quality of life: A systematic literature review. Blood Cancer Journal, 5(4), e305. https://doi.org/10.1038/bcj.2015.29
Casirati, G., Cosentino, A., Mucci, A., Salah Mahmoud, M., Ugarte Zabala, I., Zeng, J., Ficarro, S. B., Klatt, D., Brendel, C., Rambaldi, A., Ritz, J., Marto, J. A., Pellin, D., Bauer, D. E., Armstrong, S. A., & Genovese, P. (2023). Epitope editing enables targeted immunotherapy of acute myeloid leukemia. Nature, 621(7978), 404–414. https://doi.org/10.1038/s41586-023-06496-5
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020). ‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges. Nature Reviews Drug Discovery, 19(3), 185–199. https://doi.org/10.1038/s41573-019-0051-2
DiAndreth, B., Hamburger, A. E., Xu, H., & Kamb, A. (2022). The Tmod cellular logic gate as a solution for tumor-selective immunotherapy. Clinical Immunology, 241, 109030. https://doi.org/10.1016/j.clim.2022.109030
Drent, E., Themeli, M., Poels, R., de Jong-Korlaar, R., Yuan, H., de Bruijn, J., Martens, A. C. M., Zweegman, S., van de Donk, N. W. C. J., Groen, R. W. J., Lokhorst, H. M., & Mutis, T. (2017). A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 25(8), 1946–1958. https://doi.org/10.1016/j.ymthe.2017.04.024
Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou-el-Enein, M. (2023). Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nature Reviews Clinical Oncology, 20(1), 49–62. https://doi.org/10.1038/s41571-022-00704-3
Guillaume, T., Rubinstein, D. B., & Symann, M. (1998). Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation. Blood, 92(5), 1471–1490. https://doi.org/10.1182/blood.V92.5.1471
Hildreth, A. D., & O’Sullivan, T. E. (2019). Tissue-Resident Innate and Innate-Like Lymphocyte Responses to Viral Infection. Viruses, 11(3), 272. https://doi.org/10.3390/v11030272
Jiang, Y., Li, Y., & Zhu, B. (2015). T-cell exhaustion in the tumor microenvironment. Cell Death & Disease, 6(6), Article 6. https://doi.org/10.1038/cddis.2015.162
Larson, S. M., Walthers, C. M., Ji, B., Ghafouri, S. N., Naparstek, J., Trent, J., Chen, J. M., Roshandell, M., Harris, C., Khericha, M., Schweppe, T., Berent-Maoz, B., Gosliner, S. B., Almaktari, A., Ceja, M. A., Allen-Auerbach, M. S., Said, J., Nawaly, K., Mead, M., … Chen, Y. Y. (2023). CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discovery, 13(3), 580–597. https://doi.org/10.1158/2159-8290.CD-22-0964
Maman, S., & Witz, I. P. (2018). A history of exploring cancer in context. Nature Reviews Cancer, 18(6), 359–376. https://doi.org/10.1038/s41568-018-0006-7
Melenhorst, J. J., Chen, G. M., Wang, M., Porter, D. L., Chen, C., Collins, M. A., Gao, P., Bandyopadhyay, S., Sun, H., Zhao, Z., Lundh, S., Pruteanu-Malinici, I., Nobles, C. L., Maji, S., Frey, N. V., Gill, S. I., Loren, A. W., Tian, L., Kulikovskaya, I., … June, C. H. (2022). Decade-long leukemia remissions with persistence of CD4+ CAR T cells. Nature, 602(7897), Article 7897. https://doi.org/10.1038/s41586-021-04390-6
Mosti, L., Langner, L. M., Chmielewski, K. O., Arbuthnot, P., Alzubi, J., & Cathomen, T. (2021). Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. Gene Therapy, 28(9), Article 9. https://doi.org/10.1038/s41434-021-00220-6
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 17(3), 147–167. https://doi.org/10.1038/s41571-019-0297-y
Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11(4), 69. https://doi.org/10.1038/s41408-021-00459-7
Sweeney, C., & Vyas, P. (2019). The Graft-Versus-Leukemia Effect in AML. Frontiers in Oncology, 9, 1217. https://doi.org/10.3389/fonc.2019.01217
Tousley, A. M., Rotiroti, M. C., Labanieh, L., Rysavy, L. W., Kim, W.-J., Lareau, C., Sotillo, E., Weber, E. W., Rietberg, S. P., Dalton, G. N., Yin, Y., Klysz, D., Xu, P., de la Serna, E. L., Dunn, A. R., Satpathy, A. T., Mackall, C. L., & Majzner, R. G. (2023). Co-opting signaling molecules enables logic-gated control of CAR T cells. Nature, 615(7952), Article 7952. https://doi.org/10.1038/s41586-023-05778-2
Wellhausen, N., O’Connell, R. P., Lesch, S., Engel, N. W., Rennels, A. K., Gonzales, D., Herbst, F., Young, R. M., Garcia, K. C., Weiner, D., June, C. H., & Gill, S. I. (2023). Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Science Translational Medicine, 15(714), eadi1145. https://doi.org/10.1126/scitranslmed.adi1145
Yates, L. R., & Campbell, P. J. (2012). Evolution of the cancer genome. Nature Reviews Genetics, 13(11), Article 11. https://doi.org/10.1038/nrg3317
Zoine, J. T., Moore, S. E., & Velasquez, M. P. (2022). Leukemia’s Next Top Model? Syngeneic Models to Advance Adoptive Cellular Therapy. Frontiers in Immunology, 13, 867103. https://doi.org/10.3389/fimmu.2022.867103
Published
How to Cite
Issue
Section
Copyright (c) 2023 Aidan Gavrila
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
